KR101434841B1 - 2-치환-8-알킬-7-옥소-7,8-디하이드로피리도[2,3-ｄ] 피리미딘-6-카르보니트릴 및 이의 용도 - Google Patents

2-치환-8-알킬-7-옥소-7,8-디하이드로피리도[2,3-ｄ] 피리미딘-6-카르보니트릴 및 이의 용도 Download PDF

Info

Publication number
KR101434841B1
KR101434841B1 KR1020137004979A KR20137004979A KR101434841B1 KR 101434841 B1 KR101434841 B1 KR 101434841B1 KR 1020137004979 A KR1020137004979 A KR 1020137004979A KR 20137004979 A KR20137004979 A KR 20137004979A KR 101434841 B1 KR101434841 B1 KR 101434841B1
Authority
KR
South Korea
Prior art keywords
compound
cancer
formula
oxo
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137004979A
Other languages
English (en)
Korean (ko)
Other versions
KR20130098314A (ko
Inventor
이. 프렘쿠마르 레디
엠.브이. 라마나 레디
Original Assignee
템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 filed Critical 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Publication of KR20130098314A publication Critical patent/KR20130098314A/ko
Application granted granted Critical
Publication of KR101434841B1 publication Critical patent/KR101434841B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137004979A 2010-08-05 2011-07-21 2-치환-8-알킬-7-옥소-7,8-디하이드로피리도[2,3-ｄ] 피리미딘-6-카르보니트릴 및 이의 용도 Expired - Fee Related KR101434841B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37094610P 2010-08-05 2010-08-05
US61/370,946 2010-08-05
PCT/US2011/044807 WO2012018540A1 (en) 2010-08-05 2011-07-21 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof

Publications (2)

Publication Number Publication Date
KR20130098314A KR20130098314A (ko) 2013-09-04
KR101434841B1 true KR101434841B1 (ko) 2014-08-29

Family

ID=45559737

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137004979A Expired - Fee Related KR101434841B1 (ko) 2010-08-05 2011-07-21 2-치환-8-알킬-7-옥소-7,8-디하이드로피리도[2,3-ｄ] 피리미딘-6-카르보니트릴 및 이의 용도

Country Status (17)

Country Link
US (1) US8987267B2 (cg-RX-API-DMAC10.html)
EP (1) EP2600719B1 (cg-RX-API-DMAC10.html)
JP (1) JP5512894B2 (cg-RX-API-DMAC10.html)
KR (1) KR101434841B1 (cg-RX-API-DMAC10.html)
CN (1) CN103200822B (cg-RX-API-DMAC10.html)
AU (1) AU2011286282B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013002375B1 (cg-RX-API-DMAC10.html)
CA (1) CA2807498C (cg-RX-API-DMAC10.html)
DK (1) DK2600719T3 (cg-RX-API-DMAC10.html)
EA (1) EA022527B1 (cg-RX-API-DMAC10.html)
ES (1) ES2525866T3 (cg-RX-API-DMAC10.html)
IL (1) IL224555A (cg-RX-API-DMAC10.html)
MX (1) MX2013001427A (cg-RX-API-DMAC10.html)
NZ (1) NZ606281A (cg-RX-API-DMAC10.html)
PL (1) PL2600719T3 (cg-RX-API-DMAC10.html)
PT (1) PT2600719E (cg-RX-API-DMAC10.html)
WO (1) WO2012018540A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2600719E (pt) * 2010-08-05 2014-12-22 Univ Temple 8 ¿ alquilo -2 - substituído 7 ¿ oxo ¿ 7,8 ¿ diidropirido [2,3 ¿ d] pirimidina ¿ 6 ¿ carbonitrilos e seus usos
WO2014031571A1 (en) * 2012-08-21 2014-02-27 Icahn School Of Medicine At Mount Sinai Treatment of viral infections
WO2014151682A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2016015597A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CN104447739B (zh) * 2014-11-07 2016-02-17 郑州泰基鸿诺药物科技有限公司 一种氘代Palbociclib衍生物、制备方法及应用
CN104496983B (zh) 2014-11-26 2016-06-08 苏州明锐医药科技有限公司 一种帕博西尼的制备方法
CN104447743B (zh) * 2014-11-26 2016-03-02 苏州明锐医药科技有限公司 帕博西尼的制备方法
CN104478874B (zh) * 2014-12-08 2016-03-02 新发药业有限公司 一种帕博赛布的制备方法
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CN105111205B (zh) * 2015-09-12 2017-01-04 山东罗欣药业集团股份有限公司 一种帕博西尼的制备方法
US10676474B2 (en) 2016-12-16 2020-06-09 Cstone Pharmaceuticals 1,6-naphthyridine derivatives as CDK4/6 inhibitor
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
KR102286701B1 (ko) * 2018-09-28 2021-08-06 재단법인 대구경북첨단의료산업진흥재단 피리도[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CN112969463A (zh) * 2018-11-12 2021-06-15 安哥洛华治疗公司 8-环戊基-7-氧代-2-(4-哌嗪-1-基-苯基氨基)-7,8-二氢-吡啶并[2,3-d]嘧啶-6-腈及其在治疗增殖性疾病中的用途
TWI818930B (zh) * 2018-11-12 2023-10-21 美商昂可諾法治療股份有限公司 8-環戊基-7-側氧基-2-(4-哌嗪-1-基-苯基胺基)-7,8-二氫-吡啶[2,3-d]嘧啶-6-氰基及其用於治療增生性疾病的用途
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020140053A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CA3145821A1 (en) * 2019-07-02 2021-01-07 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
US20230132667A1 (en) * 2020-05-28 2023-05-04 University Of Washington Drug-like molecules and methods for the therapeutic targeting of viral rna structures
US20250129067A1 (en) 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
CA3238360A1 (en) * 2021-11-18 2023-05-25 Steven M. Fruchtman Methods and compositions for treating cancer
IL312844A (en) * 2021-11-18 2024-07-01 Onconova Therapeutics Inc Methods and compositions for treating cancer
WO2023230288A1 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
US20260183295A1 (en) * 2022-11-17 2026-07-02 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2026057047A1 (en) * 2024-09-13 2026-03-19 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Methods of treating glioma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004285A1 (en) 2004-12-30 2008-01-03 De Jonghe Steven C A Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
US20090062274A1 (en) 2005-10-07 2009-03-05 Exelixis, Inc Pyridopyrimidinone inhibitors of pi3kalpha

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
DE69939168D1 (de) * 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
SK10772002A3 (sk) * 2000-01-27 2004-01-08 Warner-Lambert Company Pyridopyrimidinónové deriváty na liečbu neurodegeneratívnych ochorení
YU63802A (sh) * 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
CA2555724A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
RU2007128961A (ru) * 2004-12-30 2009-02-10 4 Аза Ип Ив (Be) ПИРИДО(3,2-d)ПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, ПОЛЕЗНЫЕ ДЛЯ КОНСЕРВАТИВНОГО ЛЕЧЕНИЯ
WO2006135993A1 (en) * 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
US20090191193A1 (en) 2006-08-02 2009-07-30 Temple University-Of The Commonwealth System Of Higher Education Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof
BRPI0715566A2 (pt) 2006-10-16 2013-07-02 Gpc Biotech Inc composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
WO2008150260A1 (en) 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
KR101754664B1 (ko) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 피리도〔2,3-ｄ〕피리미딘-7(8ｈ)-온스 및 이의 치료 용도
PT2600719E (pt) * 2010-08-05 2014-12-22 Univ Temple 8 ¿ alquilo -2 - substituído 7 ¿ oxo ¿ 7,8 ¿ diidropirido [2,3 ¿ d] pirimidina ¿ 6 ¿ carbonitrilos e seus usos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004285A1 (en) 2004-12-30 2008-01-03 De Jonghe Steven C A Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
US20090062274A1 (en) 2005-10-07 2009-03-05 Exelixis, Inc Pyridopyrimidinone inhibitors of pi3kalpha

Also Published As

Publication number Publication date
EA022527B1 (ru) 2016-01-29
DK2600719T3 (da) 2014-12-15
CN103200822A (zh) 2013-07-10
JP2013538196A (ja) 2013-10-10
AU2011286282B2 (en) 2014-08-21
CN103200822B (zh) 2014-12-24
KR20130098314A (ko) 2013-09-04
MX2013001427A (es) 2013-06-13
US8987267B2 (en) 2015-03-24
PT2600719E (pt) 2014-12-22
CA2807498C (en) 2017-02-07
EP2600719A1 (en) 2013-06-12
NZ606281A (en) 2014-09-26
AU2011286282A1 (en) 2013-02-14
JP5512894B2 (ja) 2014-06-04
WO2012018540A1 (en) 2012-02-09
CA2807498A1 (en) 2012-02-09
US20130131058A1 (en) 2013-05-23
EP2600719B1 (en) 2014-10-08
BR112013002375B1 (pt) 2020-05-12
BR112013002375A2 (pt) 2016-05-24
EP2600719A4 (en) 2014-01-01
PL2600719T3 (pl) 2015-03-31
ES2525866T3 (es) 2014-12-30
IL224555A (en) 2016-03-31
EA201390199A1 (ru) 2013-07-30

Similar Documents

Publication Publication Date Title
KR20130098314A (ko) 2-치환-8-알킬-7-옥소-7,8-디하이드로피리도[2,3-ｄ] 피리미딘-6-카르보니트릴 및 이의 용도
US8765755B2 (en) N-containing heterocyclic compounds
JP2013502404A (ja) ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物
KR20190104632A (ko) 트라이사이클릭 자이라제 억제제
EP1325009B1 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
JP6797923B2 (ja) Ａｌｋおよびｓｒｐｋ阻害剤ならびに使用方法
AU2002211827A1 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
CN116528871A (zh) 一种吡唑并喹唑啉类化合物、其制备方法及应用
CN111868060B (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
KR101754664B1 (ko) 치환된 피리도〔2,3-ｄ〕피리미딘-7(8ｈ)-온스 및 이의 치료 용도
ES2747423T3 (es) Compuesto de quinoxalina
CA2994036A1 (en) Novel fused pyrimidinone and triazinone derivatives, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents
CN111825694A (zh) 稠环化合物、其制备方法及用途
CN108912095B (zh) 苯并咪唑类化合物及其制备方法和应用
CN114230557B (zh) 喹唑啉取代的1,2,3-三氮唑衍生物及其药物组合物、制备方法和用途
AU2010330863B2 (en) Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
CN122036626A (zh) 嘧啶-2(1h)-酮衍生物、其药物组合物及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170810

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180808

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190808

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250822

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250822

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250822